A novel binding assay for detection of 14-3-3 protein in cerebrospinal fluid from Creutzfeldt-Jakob patients

Autor: Leuck J, Peoch K, Jl, Laplanche, Grabar E, Werner E.G. Müller, Hc, Schröder

Publikováno v: Europe PubMed Central

Here we describe a simple and fast microplate assay for 14-3-3 protein, which is based on the binding of 14-3-3 protein to a chemically synthesized peptide containing the phosphorylated recognition sequence of this protein. The peptide is covalently

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d78c72b723fc9f35150ad4af13645132
https://pubmed.ncbi.nlm.nih.gov/11075958

Exigency and Going Astray1.

Autor: Jean JL Laplanche

Publikováno v: Psychoanalysis, Culture & Society; Aug2006, Vol. 11 Issue 2, p185-189, 5p

Genome wide association study of clinical duration and age at onset of sporadic CJD.

Autor: Hummerich H; MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom., Speedy H; MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom., Campbell T; MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom., Darwent L; MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom., Hill E; MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom., Collins S; Australian National Creutzfeldt-Jakob Disease Registry, The Florey, Department of Medicine (RMH), The University of Melbourne, Victoria, Australia., Stehmann C; Australian National Creutzfeldt-Jakob Disease Registry, The Florey, Department of Medicine (RMH), The University of Melbourne, Victoria, Australia., Kovacs GG; Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Ontario, Toronto, Canada.; Laboratory Medicine Program & Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna and Austrian Reference Center for Human Prion Diseases (ÖRPE), Vienna, Austria., Geschwind MD; UCSF Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, United States of America., Frontzek K; Institute of Neuropathology, University of Zürich, Zürich, Switzerland., Budka H; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna and Austrian Reference Center for Human Prion Diseases (ÖRPE), Vienna, Austria., Gelpi E; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna and Austrian Reference Center for Human Prion Diseases (ÖRPE), Vienna, Austria., Aguzzi A; Institute of Neuropathology, University of Zürich, Zürich, Switzerland., van der Lee SJ; Section Genomics of Neurodegenerative Diseases and Aging, Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.; Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands., van Duijn CM; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Liberski PP; Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland., Calero M; Chronic Disease Programme (UFIEC-CROSADIS) and Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Sanchez-Juan P; Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Research Platforms, Madrid, Spain., Bouaziz-Amar E; Department of Biochemistry and Molecular Biology, Lariboisière Hospital, GHU AP-HP Nord, University of Paris Cité, Paris, France., Laplanche JL; Department of Biochemistry and Molecular Biology, Lariboisière Hospital, GHU AP-HP Nord, University of Paris Cité, Paris, France., Haïk S; Paris Brain Institute (Institut du Cerveau, ICM), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Brandel JP; Paris Brain Institute (Institut du Cerveau, ICM), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Mammana A; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy., Capellari S; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Poleggi A; Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy., Ladogana A; Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy., Pocchiari M; Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy., Zafar S; Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, University Medical School, Göttingen, Germany.; Biomedical Engineering and Sciences Department, School of Mechanical and Manufacturing Engineering, National University of Sciences and Technology, Islamabad, Pakistan., Booth S; Prion Disease Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Jansen GH; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada., Areškevičiūtė A; Danish Reference Center for Prion Diseases, Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Løbner Lund E; Danish Reference Center for Prion Diseases, Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Glisic K; National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH, United States of America., Parchi P; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Hermann P; Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, University Medical School, Göttingen, Germany.; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany., Zerr I; Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, University Medical School, Göttingen, Germany.; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany., Appleby BS; National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH, United States of America., Safar J; Departments of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America., Gambetti P; Departments of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America., Collinge J; MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom., Mead S; MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom.

Publikováno v: PloS one [PLoS One] 2024 Jul 26; Vol. 19 (7), pp. e0304528. Date of Electronic Publication: 2024 Jul 26 (Print Publication: 2024).

An epigenetic candidate-gene association study of parental styles in suicide attempters with substance use disorders.

Autor: Chrétienneau C; Département Universitaire de Psychiatrie et de Médecine Addictologique, GHU APHP. Nord, Assistance Publique - Hôpitaux de Paris, Paris, France.; INSERM UMR-S 1144, Optimisation Thérapeutique en Neurospsychopharmacologie, OTeN, Université Paris Cité, Paris, France.; FHU NOR-SUD Network of Research in Substance Use Disorders, Paris, France., Spindola LM; NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway.; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway., Vorspan F; Département Universitaire de Psychiatrie et de Médecine Addictologique, GHU APHP. Nord, Assistance Publique - Hôpitaux de Paris, Paris, France.; INSERM UMR-S 1144, Optimisation Thérapeutique en Neurospsychopharmacologie, OTeN, Université Paris Cité, Paris, France.; FHU NOR-SUD Network of Research in Substance Use Disorders, Paris, France., Lagerberg TV; Division of Mental Health and Addiction,  Department of Psychology, Faculty of Social Sciences, Oslo University Hospital | University of Oslo, Oslo, Norway, Oslo, Norway., Marie-Claire C; INSERM UMR-S 1144, Optimisation Thérapeutique en Neurospsychopharmacologie, OTeN, Université Paris Cité, Paris, France.; FHU NOR-SUD Network of Research in Substance Use Disorders, Paris, France., Bellivier F; Département Universitaire de Psychiatrie et de Médecine Addictologique, GHU APHP. Nord, Assistance Publique - Hôpitaux de Paris, Paris, France.; INSERM UMR-S 1144, Optimisation Thérapeutique en Neurospsychopharmacologie, OTeN, Université Paris Cité, Paris, France.; FHU NOR-SUD Network of Research in Substance Use Disorders, Paris, France., Mouly S; Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université Paris Cité, Paris, France., Laplanche JL; INSERM UMR-S 1144, Optimisation Thérapeutique en Neurospsychopharmacologie, OTeN, Université Paris Cité, Paris, France.; FHU NOR-SUD Network of Research in Substance Use Disorders, Paris, France., Bloch V; INSERM UMR-S 1144, Optimisation Thérapeutique en Neurospsychopharmacologie, OTeN, Université Paris Cité, Paris, France.; FHU NOR-SUD Network of Research in Substance Use Disorders, Paris, France.; Pharmacie Hospitalière, Assistance Publique - Hôpitaux de Paris, GHU APHP. Nord, Paris, France., Le Hellard S; NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway.; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway., Icick R; Département Universitaire de Psychiatrie et de Médecine Addictologique, GHU APHP. Nord, Assistance Publique - Hôpitaux de Paris, Paris, France.; INSERM UMR-S 1144, Optimisation Thérapeutique en Neurospsychopharmacologie, OTeN, Université Paris Cité, Paris, France.; FHU NOR-SUD Network of Research in Substance Use Disorders, Paris, France.

Publikováno v: Addiction biology [Addict Biol] 2024 Apr; Vol. 29 (4), pp. e13392.

Prospective 25-year surveillance of prion diseases in France, 1992 to 2016: a slow waning of epidemics and an increase in observed sporadic forms.

Autor: Denouel A; Paris Brain Institute (Institut du Cerveau, ICM), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France., Brandel JP; Paris Brain Institute (Institut du Cerveau, ICM), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Cellule nationale de référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Peckeu-Abboud L; Department of Clinical Sciences, Clinical Immunology Unit, Institute of Tropical Medicine, Antwerp, Belgium., Seilhean D; Paris Brain Institute (Institut du Cerveau, ICM), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France., Bouaziz-Amar E; Département de Biochimie et Biologie Moléculaire, Hôpitaux Lariboisière-Fernand Widal, Paris, France.; INSERM, UMR 1144, 'Optimisation Thérapeutique en Neuropsychopharmacologie', Paris, France., Quadrio I; Neurochemistry and Neurogenetics Unit, Department of Biochemistry and Molecular Biology, Lyon University Hospital, Bron, France.; CNRS UMR5292, INSERM U1028, University of Lyon 1, BioRan, Lyon, Paris., Oudart JB; CHU Reims, Pôle de Biologie, Service de Biochimie - Pharmacologie - Toxicologie, Reims, France.; Université de Reims Champagne-Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.; CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France., Lehmann S; Université de Montpellier, IRMB, INM, INSERM, CHU de Montpellier, Laboratoire Biochimie-Protéomique clinique, Montpellier, France., Bellecave P; CHU Bordeaux, Virology Laboratory, Bordeaux, France., Laplanche JL; Département de Biochimie et Biologie Moléculaire, Hôpitaux Lariboisière-Fernand Widal, Paris, France.; INSERM, UMR 1144, 'Optimisation Thérapeutique en Neuropsychopharmacologie', Paris, France., Haik S; Paris Brain Institute (Institut du Cerveau, ICM), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Cellule nationale de référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Publikováno v: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2023 Dec; Vol. 28 (50).